Abstract
Objectives
To assess the preoperative serum levels of CA 125 with its diagnostic role and to evaluate the p53 expression in patients of primary ovarian neoplasms. We also wished to judge their relationship with other parameters like clinical staging and histopathologic tumor type.
Materials and Methods
The present study was conducted on 86 patients during the study period of 2.5 years. Preoperative CA 125 levels were evaluated by an automated immunoassay analyzer. p53 expression was judged immunohistochemically with pre-diluted monoclonal antibody. An objective scoring was done depending on distinct nuclear immunopositivity.
Results
Median value of preoperative CA 125 levels was 32 U/mL in benign surface epithelial-stromal tumors (BSEST), 53 U/mL in borderline surface epithelial-stromal tumors (BOT), 346 U/mL in malignant surface epithelial-stromal tumors (MSEST) and 560 U/mL in serous adenocarcinomas (SAC). Most of ovarian tumors were in the FIGO stage I (64 cases, 74.4%), but higher stages (II, III, IV) were observed mostly in MSESTs. SACs displayed the maximum p53 expression. Considering the cut-off value of more than 35 U/mL in CA 125 levels, the sensitivity to diagnose MSESTs was 94.7%. Preoperative CA 125 levels strongly and positively correlated with FIGO staging and p53 expression. Similarly p53 expression strongly and positively correlated with FIGO staging and histopathological categories.
Conclusion
Higher values of preoperative CA 125 levels and higher expression p53 are associated with MSESTs and BOTs especially of serous type. They strongly correlate with each other and with tumor stage. But there is no serum CA 125 concentration that can clearly differentiate benign and malignant ovarian masses.
Similar content being viewed by others
References
Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival—a review of the epidemiological literature. J Ovarian Res. 2009;2:13.
Fritsche HA, Bast RC. CA 125 in ovarian cancer: advances and controversy. Clin Chem. 1998;44:1379–80.
Kolwijck E, Thomas CM, Bulten J, et al. Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature. Int J Gynecol Cancer. 2009;19:1335–8.
Jacobs IJ, Skates S, Davies AP, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ. 1996;313:1355–8.
Giurgea LN, Ungureanu C, Mihailovici MS. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors. Rom J Morphol Embryol. 2012;53:967–73.
Yemelyanova A, Vang R, Kshirsagar M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011;24:1248–53.
Høgdall EV, Christensen L, Høgdall CK, et al. Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas. APMIS. 2008;116:400–9.
Mogensen O, Mogensen B, Jakobsen A. CA 125 in the diagnosis of pelvic masses. Eur J Cancer Clin Oncol. 1989;25:1187–90.
Chen DX, Schwartz PE, Li XG, et al. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol. 1988;72:23–7.
Cruickshank DJ, Fullerton WT, Klopper A. The clinical significance of pre-operative serum CA 125 in ovarian cancer. Br J Obstet Gynaecol. 1987;94:692–5.
Lenhard MS, Nehring S, Nagel D, et al. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors. Clin Chem Lab Med. 2009;47:537–42.
Altaras MM, Goldberg GL, Levin W, et al. The value of cancer antigen-125 as a tumor marker in malignant germ cell tumors of the ovary. Gynecol Oncol. 1986;25:150–9.
DiCioccio RA, Werness BA, Peng R, et al. Correlation of TP53 mutations and p53 expression in ovarian tumors. Cancer Genet Cytogenet. 1998;105:93–102.
Henriksen R, Strang P, Wilander E, et al. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol. 1994;53:301–6.
O’Neill CJ, Deavers MT, Malpica A, et al. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol. 2005;29:1034–41.
Compliance with ethical requirements and Conflict of interest
The present study was conducted on patients of primary ovarian neoplasms in the Department of Pathology in association with the Department of Gynecology and Obstetrics after obtaining the proper approval from ethical committee of the institution and informed consent from the patients, during the study period of 2.5 years (01.07.2010–31.12.2012). The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tiwari, R.K., Saha, K., Mukhopadhyay, D. et al. Evaluation of Preoperative Serum Levels of CA 125 and Expression of p53 in Ovarian Neoplasms: A Prospective Clinicopathological Study in a Tertiary Care Hospital. J Obstet Gynecol India 66, 107–114 (2016). https://doi.org/10.1007/s13224-014-0611-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13224-014-0611-7